Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Notice of Annual General Meeting and Notice of Results
York, U.K. 23 November 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces that its Annual General Meeting ('AGM') will be held on Monday 19 December at 9.30 a.m. at the offices of Abingdon Health, York Biotech Campus, Sand Hutton, York, YO41 1LZ, United Kingdom. Furthermore, the Company will be releasing its preliminary results for the year ended 30 June 2022 on 24 November 2022.
The notice convening the AGM will be sent to shareholders today and is available on the Company's website www.abingdonhealth.com.
Enquiries:
| Abingdon Health plc | ||
| Chris Yates, Chief Executive Officer | Via Walbrook PR | |
| Melanie Ross, Chief Financial Officer |
| |
| Chris Hand, Non-Executive Chairman |
| |
|
|
| |
| Singer Capital Markets (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 7496 3000 | |
| Peter Steel, Alex Bond (Corporate Finance) |
| |
| Tom Salvesen (Corporate Broking) |
| |
| |
| |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com | |
| Paul McManus / Phillip Marriage Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082 +44 (0)7407 804 654 | |
About Abingdon Health plc
Abingdon Health is a world leading developer and manufacturer of high-quality lateral flow rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
For more information visit: www.abingdonhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.